Health-economic evaluation of magnetic resonance imaging before biopsy for diagnosis of prostate cancer;Gesundheitsökonomische Evaluation einer Magnetresonanzbildgebung vor Biopsie zur Diagnose von Prostatakarzinomen

RoFo Fortschritte auf dem Gebiet der Rontgenstrahlen und der Bildgebenden Verfahren

Volumn 183, Issue 10, 2011, Pages 925-932

  Stadlbauer, A ^a   Bernt, R ^b   Salomonowitz, E ^a   Plas, E ^b   Strunk, G ^c   Eberhardt, K ^d  

^a Diagnostik und Interventionelle Therapie   (Germany)

^b Hanusch Krankenhaus   (Germany)

^c TU DORTMUND UNIVERSITY   (Germany)

^d Krankenhaus Schloss Werneck   (Germany)

Author keywords

cost; effectiveness; health economic analysis; MR imaging; neoplasms; prostate

Indexed keywords

ARTICLE; AUSTRIA; CANCER DIAGNOSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; ECONOMIC ASPECT; GERMANY; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; QUALITY ADJUSTED LIFE YEAR; TUMOR BIOPSY;

AUSTRIA; BIOPSY; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; GERMANY; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MODELS, ECONOMIC; NATIONAL HEALTH PROGRAMS; PROSTATIC NEOPLASMS; QUALITY-ADJUSTED LIFE YEARS; SENSITIVITY AND SPECIFICITY; SURGERY, COMPUTER-ASSISTED; UNNECESSARY PROCEDURES;

EID: 80053925224     PISSN: 14389029     EISSN: 14389010     Source Type: Journal    
DOI: 10.1055/s-0031-1281601     Document Type: Article

References (49)

1. Statistik Austria. Krebsinzidenz und Krebsmortalität in Österreich. Wien Bundesanstalt Statistik Österreich 2010
2. Robert Koch-Institut, Gesellschaft der epidemiologischen Krebsregister in Deutschland. Krebs in Deutschland 2005 / 2006. Häufigkeiten und Trends. Berlin Robert Koch-Institut (RKI) und Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V 2010
3. Robert Koch-Institut. Gesundheitsberichterstattung des Bundes: Heft 36 Prostataerkrankungen. Berlin Robert Koch-Institut (RKI) 2007
4. Bonkhoff K, Fornara P, Gleißner J et al. Leitlinie PSA-Bestimmung in der Prostatakarzinomdiagnostik (Früherkennung des Prostatakarzinoms) Vollversion. Düsseldorf Deutsche Gesellschaft für Urologie 2002
5. Deutsche Gesellschaft für Urologie. Interdisziplinäre Leitlinie der Qualität S 3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms. Düsseldorf Deutsche Gesellschaft für Urologie (e. V.) 2009
6. Ahmed H U., Kirkham A, Arya M et al. Is it time to consider a role for MRI before prostate biopsy? Nat Rev Clin Oncol 2009 6 197-206
7. Cotic C, Hammes C, Lingenfelder T. BASICS Urologie. München Elsevier 2009
8. McLernon D J., Donnan P T., Gray M et al. Receiver operating characteristics of the prostate specific antigen test in an unselected population. J Med Screen 2006 13 102-107 (Pubitemid 43925926)
9. Song J M., Kim C B., Chung H C. et al. Prostate-specific antigen, digital rectal examination and transrectal ultrasonography: a meta-analysis for this diagnostic triad of prostate cancer in symptomatic korean men. Yonsei Med J 2005 46 414-424 (Pubitemid 40959884)
10. Roehl K A., Antenor J A., Catalona W J. Serial biopsy results in prostate cancer screening study. J Urol 2002 167 2435-2439 (Pubitemid 34533140)
11. Chen M, Dang H D., Wang J Y. et al. Prostate cancer detection: comparison of T 2-weighted imaging, diffusion-weighted imaging, proton magnetic resonance spectroscopic imaging, and the three techniques combined. Acta Radiol 2008 49 602-610
12. Siebert U. Entscheidungsanalytische Modelle zur Sicherung der Übertragbarkeit internationaler Evidenz von HTA auf den Kontext des deutschen Gesundheitssystems. Berlin Deutsche Agentur für Health Technology Assessment des Deutschen Instituts für Medizinische Dokumentation und Information 2005
13. Philips Z, Ginnelly L, Sculpher M et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 2004 8 1-158
14. Menn P, Holle R. Comparing three software tools for implementing markov models for health economic evaluations. Pharmacoeconomics 2009 27 745-753
15. Reitsma J B., Glas A S., Rutjes A W. et al. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 2005 58 982-990 (Pubitemid 41316441)
16. Aus G, Becker C, Franzen S et al. Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio. Eur Urol 2004 45 160-165 (Pubitemid 38147821)
17. Gosselaar C, Roobol M J., Bergh R C. et al. Digital rectal examination and the diagnosis of prostate cancer a study based on 8 years and three screenings within the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam. Eur Urol 2009 55 139-146
18. Lopez-Corona E van den, Ohori M, Scardino P T. et al. A nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session. J Urol 2003 170 1184-1188 (Pubitemid 37108108)
19. Pinsky P F., Crawford E D., Kramer B S. et al. Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial. BJU Int 2007 99 775-779 (Pubitemid 46439580)
20. Steiner H, Moser P, Hager M et al. Clinical and pathologic features of prostate cancer detected after repeat false-negative biopsy in a screening population. Prostate 2004 58 277-282 (Pubitemid 38168925)
21. Zackrisson B, Aus G, Bergdahl S et al. The risk of finding focal cancer (less than 3 mm) remains high on re-biopsy of patients with persistently increased prostate specific antigen but the clinical significance is questionable. J Urol 2004 171 1500-1503 (Pubitemid 38365405)
22. Statistisches Bundesamt Deutschland. Lebenserwartung in Deutschland: Durchschnittliche und fernere Lebenserwartung nach ausgewählten Altersstufen. Wiesbaden Statistisches Bundesamt Deutschland 2008
23. Cowen M E., Halasyamani L K., Kattan M W. Predicting life expectancy in men with clinically localized prostate cancer. J Urol 2006 175 99-103 (Pubitemid 41797102)
24. Tewari A, Johnson C C., Divine G et al. Long-term survival probability in men with clinically localized prostate cancer: a case-control, propensity modeling study stratified by race, age, treatment and comorbidities. J Urol 2004 171 1513-1519 (Pubitemid 38365408)
25. Walz J, Gallina A, Saad F et al. A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol 2007 25 3576-3581 (Pubitemid 47372594)
26. Kim H L., Puymon M R., Qin M et al. A method for using life tables to estimate lifetime risk for prostate cancer death. J Natl Compr Canc Netw 2010 8 148-154
27. Ishihara M, Suzuki H, Akakura K et al. Baseline health-related quality of life in the management of prostate cancer. Int J Urol 2006 13 920-925 (Pubitemid 44049919)
28. Kozlowski P, Chang S D., Jones E C. et al. Combined diffusion-weighted and dynamic contrast-enhanced MRI for prostate cancer diagnosis correlation with biopsy and histopathology. J Magn Reson Imaging 2006 24 108-113
29. Tanimoto A, Nakashima J, Kohno H et al. Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T 2-weighted imaging. J Magn Reson Imaging 2007 25 146-152 (Pubitemid 46095209)
30. Hara N, Okuizumi M, Koike H et al. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a useful modality for the precise detection and staging of early prostate cancer. Prostate 2005 62 140-147 (Pubitemid 40096780)
31. Ito H, Kamoi K, Yokoyama K et al. Visualization of prostate cancer using dynamic contrast-enhanced MRI: comparison with transrectal power Doppler ultrasound. Br J Radiol 2003 76 617-624
32. Puech P, Potiron E, Lemaitre L et al. Dynamic contrast-enhanced-magnetic resonance imaging evaluation of intraprostatic prostate cancer: correlation with radical prostatectomy specimens. Urology 2009 74 1094-1099
33. Villers A, Puech P, Mouton D et al. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. J Urol 2006 176 2432-2437 (Pubitemid 44665992)
34. Miao H, Fukatsu H, Ishigaki T. Prostate cancer detection with 3-T MRI: comparison of diffusion-weighted and T 2-weighted imaging. Eur J Radiol 2007 61 297-302 (Pubitemid 46096691)
35. Casciani E, Polettini E, Bertini L et al. Contribution of the MR spectroscopic imaging in the diagnosis of prostate cancer in the peripheral zone. Abdom Imaging 2007 32 796-802 (Pubitemid 350060499)
36. Costouros N G., Coakley F V., Westphalen A C. et al. Diagnosis of prostate cancer in patients with an elevated prostate-specific antigen level: role of endorectal MRI and MR spectroscopic imaging. Am J Roentgenol 2007 188 812-816
37. Kumar V, Jagannathan N R., Kumar R et al. Transrectal ultrasound-guided biopsy of prostate voxels identified as suspicious of malignancy on three-dimensional (1)H MR spectroscopic imaging in patients with abnormal digital rectal examination or raised prostate specific antigen level of 4 10ng/ml. NMR Biomed 2007 20 11-20 (Pubitemid 46332437)
38. Testa C, Schiavina R, Lodi R et al. Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT. Radiology 2007 244 797-806 (Pubitemid 47292091)
39. Yuen J S., Thng C H., Tan P H. et al. Endorectal magnetic resonance imaging and spectroscopy for the detection of tumor foci in men with prior negative transrectal ultrasound prostate biopsy. J Urol 2004 171 1482-1486 (Pubitemid 38365401)
40. Kubota Y, Kamei S, Nakano M et al. The potential role of prebiopsy magnetic resonance imaging combined with prostate-specific antigen density in the detection of prostate cancer. Int J Urol 2008 15 322-326
41. Andriole G L., Crawford E D., Grubb 3 rd R L. et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009 360 1310-1319
42. Esserman L, Shieh Y, Thompson I. Rethinking screening for breast cancer and prostate cancer. Jama 2009 302 1685-1692
43. Lawrentschuk N, Fleshner N. The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels. BJU Int 2009 103 730-733
44. Mueller-Lisse U G., Scherr M K. Proton MR spectroscopy of the prostate. Eur J Radiol 2007 63 351-360 (Pubitemid 47321931)
45. Huppertz A, Schmidt M, Wagner M et al. Whole-body MR imaging versus sequential multimodal diagnostic algorithm for staging patients with rectal cancer: cost analysis. Fortschr Röntgenstr 2010 182 793-802
46. Jager G J., Severens J L., Thornbury J R. et al. Prostate cancer staging: should MR imaging be used? A decision analytic approach. Radiology 2000 215 445-451 (Pubitemid 30237843)
47. Hovels A M., Heesakkers R A., Adang E M. et al. Cost-effectiveness of MR lymphography for the detection of lymph node metastases in patients with prostate cancer. Radiology 2009 252 729-736
48. Hovels A M., Heesakkers R A., Adang E M. et al. Cost-analysis of staging methods for lymph nodes in patients with prostate cancer: MRI with a lymph node-specific contrast agent compared to pelvic lymph node dissection or CT. Eur Radiol 2004 14 1707-1712 (Pubitemid 39232905)
49. Katscher U, Bornert P, Leussler C et al. Transmit SENSE. Magn Reson Med 2003 49 144-150 (Pubitemid 36042344)